摘要:
A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein A represents a C3 to C12 cycloalkyl group which may be substituted by one to three selected from a fluoro group, a hydroxy group, a C1 to C6 alkyl group, etc; R1, R2, and R3 each independently represent a hydrogen atom, a fluoro group, or a C1 to C6 alkyl group; R4 represents a hydrogen atom or a prodrug group; and Y represents —CH2—CHR5—CH2—NHR6 (wherein R5 represents a hydrogen atom, a C1 to C6 alkyl group, or a C1 to C6 alkoxy group, and R6 represents a hydrogen atom or a prodrug group), or the like exhibits excellent TAFIa inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, and the like.
摘要:
A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein A represents a C3 to C12 cycloalkyl group which may be substituted by one to three selected from a fluoro group, a hydroxy group, a C1 to C6 alkyl group, etc; R1, R2, and R3 each independently represent a hydrogen atom, a fluoro group, or a C1 to C6 alkyl group; R4 represents a hydrogen atom or a prodrug group; and Y represents —CH2—CHR5—CH2—NHR6 (wherein R5 represents a hydrogen atom, a C1 to C6 alkyl group, or a C1 to C6 alkoxy group, and R6 represents a hydrogen atom or a prodrug group), or the like exhibits excellent TAFIa inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, and the like.
摘要:
The transformer includes a bobbin, a plurality of terminal electrode, a primary coil, a secondary coil, and a hook part. The bobbin includes a core portion extending in an axial direction, and terminal bases fixed at both ends of the core portion in the axial direction. The plurality of terminal electrode regions is provided on the terminal bases. Each terminal electrode region is provided with a wire connection part. The primary coil comprises a plurality of primary wires. The secondary coil comprises a plurality of secondary wires. The hook part is disposed between the core portion and one of the terminal electrode regions and configured to hook at least one of the primary wires and the secondary wires.
摘要:
A computer program product and computer implemented method are provided for migrating a virtual machine between servers. The virtual machine is initially operated on a first server, wherein the first server accesses the virtual machine image over a network at a memory location within fabric attached memory. The virtual machine is migrated from the first server to a second server by flushing data to the virtual machine image from cache memory associated with the virtual machine on the first server and providing the state and memory location of the virtual machine to the second server. The virtual machine may then operate on the second server, wherein the second server accesses the virtual machine image over the network at the same memory location within the fabric attached memory without copying the virtual machine image.
摘要:
It is an object of the present invention to provide polytetrafluoroethylene suitable for forming a porous polytetrafluoroethylene film using a high water-soluble surfactant with high volatility. Polytetrafluoroethylene has non-melt-secondary-processability, standard specific gravity of 2.160 or less, an average primary particle size of 150 nm or more, stress relaxation time of 500 seconds or more, and break strength of 29.7 N or more. The polytetrafluoroethylene is obtainable by emulsion polymerization of tetrafluoroethylene in the presence of a fluorinated surfactant with LogPOW of 3.4 or less.
摘要:
The present invention relates to [7-[(7S)-7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-8-methoxy-1,4-dihydro-4-oxoquinoline-3-carboxylic acid hemihydrate. This hemihydrate is stable and easy to prepare, and has excellent properties for a pharmaceutical bulk powder.
摘要:
The present invention relates to a permselective separation membrane that can be used in blood purifying treatment. More particularly, the present invention relates to a polysulfone-based permselective separation membrane which has well-balanced separation properties, highly stable safety and performance, and also can be smoothly assembled into a module, and a method for producing the same.
摘要:
The present invention relates to [7-[(7S)-7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-8-methoxy-1,4-dihydro-4-oxoquinoline-3-carboxylic acid hemihydrate. This hemihydrate is stable and easy to prepare, and has excellent properties for a pharmaceutical bulk powder.
摘要:
A compound represented by the general formula (1): -Q1-Q2-T0-N(R1)-Q3-(R2)T1Q4 (1) wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof.The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.
摘要:
The present invention provides a VLA-4 inhibitor having high water-solubility and excellent long-term stability; i.e., sodium trans-4-[1-[2,5-dichloro-4-[(1-methyl-1H-3-indolylcarbonyl)amino]phenylacetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylate pentahydrate.